Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This clinical trial in Poland found that using finasteride, alone or with an alpha-blocker, reduced prostate adenoma size by 40% and improved micturition in patients with benign prostatic hyperplasia.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This study found that finasteride treatment in benign prostatic hyperplasia patients induced a transient, caspase-dependent apoptosis in epithelial cells, with activity peaking at 6-8 days and diminishing by 27-32 days.

This case report describes two German shepherd dogs with prostatitis that showed favorable responses to treatment with finasteride, phenazopyridine, and enrofloxacin.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

This letter to the editor discusses excessive hair growth observed around local β-interferon injection sites for malignant melanoma but reports no new clinical results.

In a porcine model, this study observed that using an External Tissue Expansion Device increased epidermis thickness, cell proliferation, and vessel density at fat graft recipient sites.

This study found that testosterone therapy improved physical performance, strength, lean body mass, and serum cholesterol in older men with low testosterone levels, with or without the addition of finasteride.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study found that 60% of examined prostate tumors had new somatic substitutions in the SRD5A2 gene, affecting enzyme activity and potentially influencing prostate cancer progression.

This article discusses immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal endometriosis, introducing a new quantitative method, but reports no new experimental results.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

Finasteride and DEHP exposure during development can change reproductive markers in rats.

This study observed that finasteride treatment was more effective in treating prostatitis-related hemospermia compared to non-prostatitis cases, particularly after excluding sonographically abnormal cases.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

In this animal study, Phellodendri Cortex extract reduced prostate tissue damage and inhibited 5α-reductase gene expression in rats with experimentally induced benign prostatic hyperplasia.

This study investigated genetic and epigenetic markers for prostate cancer, reporting that certain genotype combinations may influence cancer risk or protection and identifying GSTP1 promoter methylation as a strong prognostic and diagnostic marker linked to tumor aggressiveness.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.